Flow cytometry analysis showed no significant difference in the expression of the surface markers CD90, CD73, and CD45 between normal serum-treated and HCC serum-treated hA-MSCs (Fig. S1). The gene discussed is PTPRC; the disease is hepatocellular carcinoma.